title: The N676D and G697R mutations in the kinase domain of FLT3 confer resistance to the inhibitor AC220.
authors.forename: Daphnie
authors.initials: D
authors.lastname: Pauwels
authors.forename: Bram
authors.initials: B
authors.lastname: Sweron
authors.forename: Jan
authors.initials: J
authors.lastname: Cools
mesh_terms: D019943:Amino Acid Substitution; D052160:Benzothiazoles / Q000494:pharmacology*; D045744:Cell Line, Tumor; D019008:Drug Resistance, Neoplasm / Q000235:genetics*; D005260:Female; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy / Q000201:enzymology / Q000235:genetics*; D008297:Male; D020125:Mutation, Missense; D010671:Phenylurea Compounds / Q000494:pharmacology*; D047428:Protein Kinase Inhibitors / Q000494:pharmacology*; D017434:Protein Structure, Tertiary; D051941:fms-Like Tyrosine Kinase 3 / Q000037:antagonists & inhibitors* / Q000235:genetics* / Q000378:metabolism
chemical_list: D052160:Benzothiazoles; D010671:Phenylurea Compounds; D047428:Protein Kinase Inhibitors; C544967:quizartinib; C497970:FLT3 protein, human; D051941:fms-Like Tyrosine Kinase 3